How Australia could almost eradicate H.I.V. transmissions

10 July 2019 - It took universal health care, political will and a health campaign designed to terrify the public, ...

Read more →

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

9 July 2019 - The long-acting injectable regimen has been granted priority review status by the FDA, with a target approval ...

Read more →

ViiV Healthcare receives EU marketing authorisation for Dovato (dolutegravir/lamivudine), a new once-daily, single-pill, two-drug regimen for the treatment of HIV-1 infection

3 July 2019 - Authorisation based on GEMINI pivotal trials in which Dovato achieved non-inferior efficacy compared to a dolutegravir-based, three-drug ...

Read more →

HIV diagnoses in Australia hit 18-year low, but there is still a way go

3 July 2019 - Australia has solidified its reputation as a world leader in HIV prevention, recording its lowest number ...

Read more →

FDA continues to encourage ongoing education about the benefits and risks associated with PrEP, including additional steps to help reduce the risk of getting HIV

1 July 2019 - The U.S. FDA approved Truvada (emtricitabine/tenofovir disoproxil fumarate) in 2004 for the treatment of HIV-1 infection in ...

Read more →

A million Americans need this drug. Trump’s deal won’t help enough of them.

13 May 2019 - A donation of HIV prevention drugs from the pharmaceutical giant Gilead could benefit shareholders more than patients. ...

Read more →

Janssen announces submission of new drug application to U.S. FDA for the first monthly, injectable, two drug regimen of rilpivirine and cabotegravir for treatment of HIV

29 April 2019 - If approved, the rilpivirine and cabotegravir regimen would be the first-ever long-acting injectable treatment for adults living ...

Read more →

HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement

22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...

Read more →

19,000 Australians now using PBS subsidised anti-HIV drugs

25 March 2019 - About 19,000 Australians have taken advantage of anti-HIV drugs in the first two years of groundbreaking ...

Read more →

U.S. FDA accepts sNDAs for Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)

23 January 2019 - Potential new indication would expand use to allow treatment-experienced adults living with HIV-1 whose virus is suppressed ...

Read more →

Decisions relating to the funded brands of some anti-retroviral treatments for HIV

20 December 2018 - PHARMAC is pleased to announce decisions to award sole supply for seven anti-retroviral treatments used in ...

Read more →

FDA announces pilot program with WHO to expedite review of HIV drug applications

30 November 2018 - The U.S. FDA today announced a plan to work with the WHO to pilot a process to ...

Read more →

Proposal to award sole supply and change some anti-retroviral brands

16 October 2018 - PHARMAC is seeking feedback on a proposal to make several changes to funding of anti-retroviral therapies ...

Read more →

Gilead receives approval in Canada for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for the treatment of HIV-1 infection

12 July 2018 - Gilead Sciences Canada today announced that Health Canada has granted a notice of compliance for Biktarvy (bictegravir ...

Read more →

Rapid rise in anti-HIV PrEP pills linked to drop in condom use

7 June 2018 - PrEP availability may play a part in men’s complacency about the chances of becoming infected, study suggests. ...

Read more →